Nuclear Medicine Market Projected Growth at 9.2% CAGR to Reach USD 11.4 billion by 2031 | Exclusive Research Report by Transparency Market Research Inc.
23 sept. 2024 06h58 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 23, 2024 (GLOBE NEWSWIRE) -- According to a report published by Transparency Market Research, the global nuclear...
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
20 sept. 2024 09h00 HE
|
FN Media Group LLC
PALM BEACH, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer...
Keck Graduate Institute Awarded $750,000 Grant from the Department of Energy to Study Low-Level Radiation Effects
19 sept. 2024 14h34 HE
|
Keck Graduate Institute
Claremont, CA, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Keck Graduate Institute (KGI), a member of The Claremont Colleges, has been awarded a significant grant from the Department of Energy to investigate...
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
19 sept. 2024 08h00 HE
|
AIM ImmunoTech Inc.
Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues to be generally well-tolerated with no...
Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors
19 sept. 2024 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors Lugano, Switzerland – September 19, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of...
U.S. grants Vidac Pharma patent offering broad protection of mode of action underlying its oncology drug candidates
19 sept. 2024 01h00 HE
|
Vidac Pharma Holding PLC
London (UK), September 19 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class...
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
18 sept. 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
16 sept. 2024 09h00 HE
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Medigene to Host Virtual R&D Event on Medigene’s Optimal 3S TCRs for TCR-Guided Precision Immunotherapies
16 sept. 2024 08h30 HE
|
Medigene AG
Planegg/Martinsried, September 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial
16 sept. 2024 08h00 HE
|
Allarity Therapeutics, Inc.
- Durable Clinical Benefit Observed Beyond a Year on Treatment in Heavily Pre-Treated Patients Boston (September 16, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR),...